Bruce Eaton - Jul 23, 2021 Form 3 Insider Report for Editas Medicine, Inc. (EDIT)

Role: EVP, Chief Business Officer
Signature: /s/ Bruce Eaton
Stock symbol: EDIT
Transactions as of: Jul 23, 2021
Transactions value $: $0
Form type: 3
Date filed: 7/30/2021, 04:11 PM
Next filing: Apr 4, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Ownership	Footnotes
holding	EDIT	Common Stock						28.3 K	Jul 23, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	EDIT	Stock Option (right to buy)							Jul 23, 2021	Common Stock	110 K	$33.98	Direct	F2
holding	EDIT	Stock Option (right to buy)							Jul 23, 2021	Common Stock	48.8 K	$21.10	Direct	F3
holding	EDIT	Stock Option (right to buy)							Jul 23, 2021	Common Stock	45 K	$28.05	Direct	F4
holding	EDIT	Stock Option (right to buy)							Jul 23, 2021	Common Stock	17.1 K	$45.69	Direct	F5

Explanation of Responses:

Id	Content
F1	Reflects (i) 9,830 shares of common stock and (ii) 18,483 shares of common stock received by the Reporting Person in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, of which (A) 3,555 shares are scheduled to vest over four years with 25% of the units having vested on February 6, 2020 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2023, (B) 5,157 shares are scheduled to vest over four years with 25% of the units having vested on February 6, 2021 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 6, 2024, (C) 4,289 shares are scheduled to vest in full on March 31, 2022, and (D) 5,482 shares are scheduled to vest over four years with 25% of the units vesting on March 2, 2022 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2025.
F2	This option was granted on February 5, 2018 and is scheduled to vest over four years, with 25% of the shares having vested on January 22, 2019 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through January 22, 2022.
F3	This option was granted on February 6, 2019 and is scheduled to vest over four years in equal monthly installments beginning on March 6, 2019 through February 6, 2023.
F4	This option was granted on February 6, 2020 and is scheduled to vest over four years in equal monthly installments beginning on March 6, 2020 through February 6, 2024.
F5	This option was granted on March 2, 2021 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2021 through March 2, 2025.